Browse HMOX1

Summary
SymbolHMOX1
Nameheme oxygenase 1
Aliases bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Microsome Endoplasmic reticulum membrane Peripheral membrane protein Cytoplasmic side
Domain PF01126 Heme oxygenase
Function

Heme oxygenase cleaves the heme ring at the alpha methene bridge to form biliverdin. Biliverdin is subsequently converted to bilirubin by biliverdin reductase. Under physiological conditions, the activity of heme oxygenase is highest in the spleen, where senescent erythrocytes are sequestrated and destroyed. Exhibits cytoprotective effects since excess of free heme sensitizes cells to undergo apoptosis.

> Gene Ontology
 
Biological Process GO:0000302 response to reactive oxygen species
GO:0001525 angiogenesis
GO:0001666 response to hypoxia
GO:0001818 negative regulation of cytokine production
GO:0001819 positive regulation of cytokine production
GO:0001889 liver development
GO:0001935 endothelial cell proliferation
GO:0002246 wound healing involved in inflammatory response
GO:0002262 myeloid cell homeostasis
GO:0002263 cell activation involved in immune response
GO:0002274 myeloid leukocyte activation
GO:0002275 myeloid cell activation involved in immune response
GO:0002279 mast cell activation involved in immune response
GO:0002366 leukocyte activation involved in immune response
GO:0002367 cytokine production involved in immune response
GO:0002440 production of molecular mediator of immune response
GO:0002443 leukocyte mediated immunity
GO:0002444 myeloid leukocyte mediated immunity
GO:0002448 mast cell mediated immunity
GO:0002683 negative regulation of immune system process
GO:0002685 regulation of leukocyte migration
GO:0002686 negative regulation of leukocyte migration
GO:0002694 regulation of leukocyte activation
GO:0002695 negative regulation of leukocyte activation
GO:0002697 regulation of immune effector process
GO:0002698 negative regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002700 regulation of production of molecular mediator of immune response
GO:0002701 negative regulation of production of molecular mediator of immune response
GO:0002703 regulation of leukocyte mediated immunity
GO:0002704 negative regulation of leukocyte mediated immunity
GO:0002718 regulation of cytokine production involved in immune response
GO:0002719 negative regulation of cytokine production involved in immune response
GO:0002886 regulation of myeloid leukocyte mediated immunity
GO:0002887 negative regulation of myeloid leukocyte mediated immunity
GO:0003012 muscle system process
GO:0003013 circulatory system process
GO:0003018 vascular process in circulatory system
GO:0006778 porphyrin-containing compound metabolic process
GO:0006787 porphyrin-containing compound catabolic process
GO:0006788 heme oxidation
GO:0006875 cellular metal ion homeostasis
GO:0006879 cellular iron ion homeostasis
GO:0006887 exocytosis
GO:0006914 autophagy
GO:0006979 response to oxidative stress
GO:0007249 I-kappaB kinase/NF-kappaB signaling
GO:0007584 response to nutrient
GO:0007588 excretion
GO:0008015 blood circulation
GO:0008217 regulation of blood pressure
GO:0008625 extrinsic apoptotic signaling pathway via death domain receptors
GO:0008630 intrinsic apoptotic signaling pathway in response to DNA damage
GO:0009266 response to temperature stimulus
GO:0009408 response to heat
GO:0009991 response to extracellular stimulus
GO:0010035 response to inorganic substance
GO:0010038 response to metal ion
GO:0010039 response to iron ion
GO:0010506 regulation of autophagy
GO:0010508 positive regulation of autophagy
GO:0010656 negative regulation of muscle cell apoptotic process
GO:0010657 muscle cell apoptotic process
GO:0010660 regulation of muscle cell apoptotic process
GO:0014805 smooth muscle adaptation
GO:0014806 smooth muscle hyperplasia
GO:0014900 muscle hyperplasia
GO:0016236 macroautophagy
GO:0016239 positive regulation of macroautophagy
GO:0016241 regulation of macroautophagy
GO:0017157 regulation of exocytosis
GO:0019439 aromatic compound catabolic process
GO:0030336 negative regulation of cell migration
GO:0031099 regeneration
GO:0031100 animal organ regeneration
GO:0031667 response to nutrient levels
GO:0031668 cellular response to extracellular stimulus
GO:0031669 cellular response to nutrient levels
GO:0031670 cellular response to nutrient
GO:0032386 regulation of intracellular transport
GO:0032387 negative regulation of intracellular transport
GO:0032418 lysosome localization
GO:0032602 chemokine production
GO:0032642 regulation of chemokine production
GO:0032722 positive regulation of chemokine production
GO:0032762 mast cell cytokine production
GO:0032763 regulation of mast cell cytokine production
GO:0032764 negative regulation of mast cell cytokine production
GO:0033002 muscle cell proliferation
GO:0033003 regulation of mast cell activation
GO:0033004 negative regulation of mast cell activation
GO:0033006 regulation of mast cell activation involved in immune response
GO:0033007 negative regulation of mast cell activation involved in immune response
GO:0033013 tetrapyrrole metabolic process
GO:0033015 tetrapyrrole catabolic process
GO:0034101 erythrocyte homeostasis
GO:0034381 plasma lipoprotein particle clearance
GO:0034383 low-density lipoprotein particle clearance
GO:0034395 regulation of transcription from RNA polymerase II promoter in response to iron
GO:0034599 cellular response to oxidative stress
GO:0034605 cellular response to heat
GO:0035094 response to nicotine
GO:0035150 regulation of tube size
GO:0036293 response to decreased oxygen levels
GO:0036294 cellular response to decreased oxygen levels
GO:0040013 negative regulation of locomotion
GO:0042033 chemokine biosynthetic process
GO:0042035 regulation of cytokine biosynthetic process
GO:0042089 cytokine biosynthetic process
GO:0042107 cytokine metabolic process
GO:0042108 positive regulation of cytokine biosynthetic process
GO:0042167 heme catabolic process
GO:0042168 heme metabolic process
GO:0042311 vasodilation
GO:0042312 regulation of vasodilation
GO:0042440 pigment metabolic process
GO:0042542 response to hydrogen peroxide
GO:0043122 regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043123 positive regulation of I-kappaB kinase/NF-kappaB signaling
GO:0043279 response to alkaloid
GO:0043299 leukocyte degranulation
GO:0043300 regulation of leukocyte degranulation
GO:0043301 negative regulation of leukocyte degranulation
GO:0043303 mast cell degranulation
GO:0043304 regulation of mast cell degranulation
GO:0043305 negative regulation of mast cell degranulation
GO:0043392 negative regulation of DNA binding
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0043500 muscle adaptation
GO:0043523 regulation of neuron apoptotic process
GO:0043524 negative regulation of neuron apoptotic process
GO:0043618 regulation of transcription from RNA polymerase II promoter in response to stress
GO:0043619 regulation of transcription from RNA polymerase II promoter in response to oxidative stress
GO:0043620 regulation of DNA-templated transcription in response to stress
GO:0043627 response to estrogen
GO:0044057 regulation of system process
GO:0044270 cellular nitrogen compound catabolic process
GO:0045055 regulated exocytosis
GO:0045073 regulation of chemokine biosynthetic process
GO:0045080 positive regulation of chemokine biosynthetic process
GO:0045576 mast cell activation
GO:0045765 regulation of angiogenesis
GO:0045766 positive regulation of angiogenesis
GO:0045909 positive regulation of vasodilation
GO:0045920 negative regulation of exocytosis
GO:0046149 pigment catabolic process
GO:0046685 response to arsenic-containing substance
GO:0046686 response to cadmium ion
GO:0046700 heterocycle catabolic process
GO:0046916 cellular transition metal ion homeostasis
GO:0048514 blood vessel morphogenesis
GO:0048659 smooth muscle cell proliferation
GO:0048660 regulation of smooth muscle cell proliferation
GO:0048661 positive regulation of smooth muscle cell proliferation
GO:0048662 negative regulation of smooth muscle cell proliferation
GO:0048732 gland development
GO:0048872 homeostasis of number of cells
GO:0050673 epithelial cell proliferation
GO:0050755 chemokine metabolic process
GO:0050777 negative regulation of immune response
GO:0050865 regulation of cell activation
GO:0050866 negative regulation of cell activation
GO:0050880 regulation of blood vessel size
GO:0050900 leukocyte migration
GO:0051048 negative regulation of secretion
GO:0051051 negative regulation of transport
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051098 regulation of binding
GO:0051100 negative regulation of binding
GO:0051101 regulation of DNA binding
GO:0051186 cofactor metabolic process
GO:0051187 cofactor catabolic process
GO:0051259 protein oligomerization
GO:0051260 protein homooligomerization
GO:0051271 negative regulation of cellular component movement
GO:0051402 neuron apoptotic process
GO:0051640 organelle localization
GO:0051656 establishment of organelle localization
GO:0055072 iron ion homeostasis
GO:0055076 transition metal ion homeostasis
GO:0060627 regulation of vesicle-mediated transport
GO:0061008 hepaticobiliary system development
GO:0061082 myeloid leukocyte cytokine production
GO:0070482 response to oxygen levels
GO:0070997 neuron death
GO:0071241 cellular response to inorganic substance
GO:0071243 cellular response to arsenic-containing substance
GO:0071248 cellular response to metal ion
GO:0071276 cellular response to cadmium ion
GO:0071281 cellular response to iron ion
GO:0071453 cellular response to oxygen levels
GO:0071456 cellular response to hypoxia
GO:0071496 cellular response to external stimulus
GO:0072718 response to cisplatin
GO:0072719 cellular response to cisplatin
GO:0090066 regulation of anatomical structure size
GO:0090594 inflammatory response to wounding
GO:0097006 regulation of plasma lipoprotein particle levels
GO:0097191 extrinsic apoptotic signaling pathway
GO:0097193 intrinsic apoptotic signaling pathway
GO:0097421 liver regeneration
GO:1901214 regulation of neuron death
GO:1901215 negative regulation of neuron death
GO:1901342 regulation of vasculature development
GO:1901361 organic cyclic compound catabolic process
GO:1901565 organonitrogen compound catabolic process
GO:1902041 regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1902042 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors
GO:1903305 regulation of regulated secretory pathway
GO:1903306 negative regulation of regulated secretory pathway
GO:1903522 regulation of blood circulation
GO:1903524 positive regulation of blood circulation
GO:1903531 negative regulation of secretion by cell
GO:1904018 positive regulation of vasculature development
GO:1904019 epithelial cell apoptotic process
GO:1904035 regulation of epithelial cell apoptotic process
GO:1904036 negative regulation of epithelial cell apoptotic process
GO:1904705 regulation of vascular smooth muscle cell proliferation
GO:1904706 negative regulation of vascular smooth muscle cell proliferation
GO:1990267 response to transition metal nanoparticle
GO:1990874 vascular smooth muscle cell proliferation
GO:2000146 negative regulation of cell motility
GO:2001233 regulation of apoptotic signaling pathway
GO:2001234 negative regulation of apoptotic signaling pathway
GO:2001236 regulation of extrinsic apoptotic signaling pathway
GO:2001237 negative regulation of extrinsic apoptotic signaling pathway
Molecular Function GO:0004392 heme oxygenase (decyclizing) activity
GO:0004620 phospholipase activity
GO:0004630 phospholipase D activity
GO:0008081 phosphoric diester hydrolase activity
GO:0016298 lipase activity
GO:0016705 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen
GO:0020037 heme binding
GO:0042578 phosphoric ester hydrolase activity
GO:0046906 tetrapyrrole binding
Cellular Component GO:0005901 caveola
GO:0044853 plasma membrane raft
GO:0045121 membrane raft
GO:0098589 membrane region
GO:0098857 membrane microdomain
> KEGG and Reactome Pathway
 
KEGG hsa04066 HIF-1 signaling pathway
hsa04978 Mineral absorption
hsa00860 Porphyrin and chlorophyll metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-189483: Heme degradation
R-HSA-168256: Immune System
R-HSA-6785807: Interleukin-4 and 13 signaling
R-HSA-917937: Iron uptake and transport
R-HSA-1430728: Metabolism
R-HSA-189445: Metabolism of porphyrins
R-HSA-449147: Signaling by Interleukins
R-HSA-382551: Transmembrane transport of small molecules
Summary
SymbolHMOX1
Nameheme oxygenase 1
Aliases bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between HMOX1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between HMOX1 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
26595750NeuroblastomaInhibit immunity (T cell function)Importantly, HO-1 inhibition abrogated immune cell paralysis affecting CD4 and CD8 T-effector cells.
28512172Prostate CarcinomaInhibit immunityIn this study, we assessed how hemin, a pharmacologic inducer of heme oxygenase-1 (HO-1), has an impact on prostate cancer development in an in vivo conditioning model. Conditioning resulted in increased tumor latency and decreased initial growth rate. Histologic analysis of tumors grown in conditioned mice revealed impaired vascularization. Hemin-treated human umbilical vein endothelial cells (HUVEC) exhibited decreased tubulogenesis in vitro only in the presence of TRAMP-C1-conditioned media. In addition, hemin boosted CD8+ T-cell proliferation and degranulation in vitro and antigen-specific cytotoxicity in vivo A significant systemic increase in CD8+ T-cell frequency was observed in preconditioned tumor-bearing mice.
24778275Lung Carcinoma; Pancreatic Ductal AdenocarcinomaInhibit immunityA basis for the function of the FAP(+)/CD45(+) subset is shown to be the immune inhibitory enzyme, heme oxygenase-1 (HO-1). The FAP(+)/CD45(+) cells are the major tumoral source of HO-1, and an inhibitor of HO-1, Sn mesoporphyrin, causes the same extent of immune-dependent arrest of LL2/OVA tumor growth as does the depletion of these cells. Because this observation of immune suppression by HO-1 expressed by the FAP(+)/CD45(+) stromal cell is replicated in a transplanted model of pancreatic ductal adenocarcinoma, we conclude that pharmacologically targeting this enzyme may improve cancer immunotherapy.
Summary
SymbolHMOX1
Nameheme oxygenase 1
Aliases bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of HMOX1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolHMOX1
Nameheme oxygenase 1
Aliases bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of HMOX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.4980.273
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.3840.891
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5720.765
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.1510.715
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.4210.816
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1990.936
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.250.676
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.2630.883
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.2490.9
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.7040.761
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8230.821
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1240.516
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of HMOX1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27730001
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27590001
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolHMOX1
Nameheme oxygenase 1
Aliases bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of HMOX1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolHMOX1
Nameheme oxygenase 1
Aliases bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of HMOX1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by HMOX1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolHMOX1
Nameheme oxygenase 1
Aliases bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of HMOX1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolHMOX1
Nameheme oxygenase 1
Aliases bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of HMOX1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolHMOX1
Nameheme oxygenase 1
Aliases bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between HMOX1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolHMOX1
Nameheme oxygenase 1
Aliases bK286B10; HO-1; heme oxygenase (decycling) 1; HMOX1D; HSP32; heat shock protein, 32-kD
Chromosomal Location22q12
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting HMOX1 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting HMOX1.
ID Name Drug Type Targets #Targets
DB00157NADHSmall MoleculeAASS, ACADS, ADH1A, ADH1B, ADH1C, ADH4, ADH5, ADH7, AKR1B1, AKR1C1 ......144
DB01942Formic AcidSmall MoleculeACYP2, CA2, CASK, CTBP1, CYTH2, FGF1, GGACT, GPHN, HMOX1, NOS1, PV ......12
DB02073Biliverdine IX AlphaSmall MoleculeBLVRB, HMOX1, MB3
DB0246812-PhenylhemeSmall MoleculeHMOX11
DB039062-PhenylhemeSmall MoleculeHMOX11
DB04803VerdohemeSmall MoleculeHMOX11
DB04912StannsoporfinSmall MoleculeHMOX1, HMOX22
DB069141-({2-[2-(4-CHLOROPHENYL)ETHYL]-1,3-DIOXOLAN-2-YL}METHYL)-1H-IMIDAZOLESmall MoleculeHMOX11
DB073421-(adamantan-1-yl)-2-(1H-imidazol-1-yl)ethanoneSmall MoleculeHMOX11